Timothy G. Bowler

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

Alexander Stratigos, Aleksandar Sekulić, Ketty Peris et al. · The Lancet Oncology · 2021 · 278 citations · Full text

Medicine, Oncology, Pharmacology +14

Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

Benjamin A. Nacev, Francisco Sánchez-Vega, Shaleigh Smith et al. · Nature Communications · 2022 · 211 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab

Ciara M. Kelly, Cristina R. Antonescu, Timothy G. Bowler et al. · JAMA Oncology · 2020 · 205 citations · Full text

Life Sciences, Immunology, Oncology +17

Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor

Gerardo A. Vitiello, Timothy G. Bowler, Mengyuan Liu et al. · Journal of Clinical Investigation · 2019 · 75 citations · Full text

Medicine, Immunology, Oncology +17

Deregulated FGF and homeotic gene expression underlies cerebellar vermis hypoplasia in CHARGE syndrome

Tian Yu, Linda C. Meiners, Katrin Danielsen et al. · eLife · 2013 · 69 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17